Global Bio-Clinical Trials 2012

Published: 18-Jul-2012

25 - 28 September 2012

Conference

The Lalit Ashok, Bangalore, India


This strategic four-day initiative will focus on challenges pertaining to the conduct of clinical trials for the approval of sensitive biopharmaceuticals and biosimilars. An interactive seminar on 'Emerging Market Regulations - Brazil, China, Russia, LATAM and Malaysia' will take place on 25 September, and an exclusive workshop on PharmacoKinetics/PharmacoDynamics studies on 28 September. The two-day conference (26-27 September) will provide solutions to dealing with the current regulatory challenges and guidelines for robust design of clinical trials, economic patient recruitment and retention protocols, latest tool and techniques for clinical data management and medical writing, along with updates on the latest pharmacovigilance trends

Organiser: CPhI Conferences

Trending Articles

  1. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  2. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  3. Pharmapack Europe<font color="red"><sup><i>new dates</i></sup></font> 13–14 October 2021 | Conference | Paris, France
  4. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  5. Lab Innovations 30-31 October 2024 | Exhibition | Birmingham, UK

You may also like

Regulatory

The big risk for US CDMOs

With many of the largest CDMOs now running at capacity, drug sponsors will need to focus on mitigating risk and building resiliency
Manufacturing

EU supply chain regulation: what will it mean for companies attending CPHI?

Ahead of her session on “Manufacturing Excellence” at CPHI Frankfurt (1–3 November), Elisabeth Stampa, President of Medicines for Europe, along with Adrian van den Hoven, Director General of Medicines for Europe, map out the impact of EU supply chain regulation on pharma companies in an exclusive article for Manufacturing Chemist
Manufacturing

Developments in global pharmaceutical excipients in the next 3–5 years: part II

Key themes that will shape the excipient landscape in the near future will include regulations, innovation, economics and sustainability, says Dr Iain Moore, Head of Global Quality Assurance, Croda International, in this year’s <i>CPhI Annual Report</i>
Manufacturing

Developments in global pharmaceutical excipients in the next 3–5 years: part I

Key themes that will shape the excipient landscape in the near future will include regulations, innovation, economics and sustainability, says Dr Iain Moore, Head of Global Quality Assurance, Croda International, in this year’s <i>CPhI Annual Report</i>
Media

Trends and opportunities in biopharmaceutical product development and manufacturing

The biopharmaceutical industry and its bioprocessing sector are healthy and continue to grow in size/revenue, breadth, importance and diversity. Worldwide sales of biopharmaceuticals are now more than $300 billion, increasing at an annual rate of about 12% annually. This growth has been relatively consistent during the past 15+ years, which is why the segment is attractive to investors, explains Eric Langer, President and Managing Partner, BioPlan Associates
Regulatory

CPhI Annual Report 2020 predicts further bio growth in China

The report has been launched ahead of the first CPhI Festival of Pharma on 5-16 October
Media

CPhI Report predicts CGT capacity shortages in the USA and mAb approvals in China

Continuous bioprocessing is growing quickly ... but from a low base ... with virtually all manufacturers now using at least some single-use technologies
Subscribe now